149
Thursday 15, October 2015
16:16 -16:22
ICCS S2-2 (LO)
SOLIFENACIN IN CHILDREN AND ADOLESCENTS WITH OVERACTIVE BLADDER: RESULTS OF A PHASE 3 CLINICAL TRIALDonald NEWGREEN
1
, Brigitte BOSMAN
1
, Will SAWYER
2
, Adriana HOLLESTEIN-
HAVELAAR
3
, Robin BESUYEN
3
, Ellen DAHLER
4
, Stéphane BOLDUC
5
and Soeren
RITTIG
6
1
Astellas Pharma Europe BV, Global Medical Science - Urology / Nephrology, Leiden,
NETHERLANDS
2
Astellas Pharma Europe BV, Global Development Operations Biostatistics II, Leiden,
NETHERLANDS
3
Astellas Pharma Europe BV, Global Development Operations, Clinical Science, Leiden,
NETHERLANDS
4
Astellas Pharma BV, Global Development Operations Clinical Study Management, Leiden,
NETHERLANDS
5
CHU de Québec, Division of Urology, Québec, CANADA
6
Aarhus University Hospital, Department of Pediatrics, Aarhus N, DENMARK
ICCS S2-2 (LO combined presentation with previous abstract)
SOLIFENACIN IN CHILDREN AND ADOLESCENTS WITH OVERACTIVE BLADDER: RESULTS OF AN OPEN-LABEL, LONG-TERM CLINICAL TRIALBrigitte BOSMAN
1
, Donald NEWGREEN
1
, Will SAWYER
2
, Adriana HOLLESTEIN-
HAVELAAR
3
, Ellen DAHLER
3
, Stéphane BOLDUC
4
and Soeren RITTIG
5
1
Astellas Pharma Europe BV, Global Medical Science - Urology / Nephrology, Leiden,
NETHERLANDS
2
Astellas Pharma Europe BV, Global Development Operations Biostatistics II, Leiden,
NETHERLANDS
3
Astellas Pharma Europe BV, Global Development Operations, Clinical Science, Leiden,
NETHERLANDS
4
CHU de Québec, Division of Urology, Québec, CANADA
5
Aarhus University Hospital, Department of Pediatrics, Aarhus N, DENMARK
16:22 -16:26
ICCS S2-3 (SO)
CHILDREN’S EXPERIENCES OF VOIDING SCHOOL INTERVENTIONAnneli SAARIKOSKI
1
, Riitta KOPPELI
2
and Anna AXELIN
3
1
Helsinki University Hospital and University of Turku, Department of nursing science, The Hospital
of Children and Adolescence, Helsinki, FINLAND
2
Helsinki University Hospital, Jorvi Hospital, Espoo, FINLAND
3
University of Turku, Department of Nursing Science, Turku, FINLAND
ICCS PROGRAMME SESSIONS
ESPU-N PROGRAMME SESSIONS
ESPU PROGRAMME SESSIONS
GENERAL INFO